Review





Similar Products

94
Bioss p pparγ
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
P Pparγ, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR+Gamma+(ser273)+Polyclonal+Antibody/pmc13754020-245-6-8
Average 94 stars, based on 1 article reviews
p pparγ - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Selleck Chemicals pparγ antagonist gw9662
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Pparγ Antagonist Gw9662, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/GW9662/pmc13745311-181-1-4
Average 93 stars, based on 1 article reviews
pparγ antagonist gw9662 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
MedChemExpress ppar γ antagonist t0070907
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Ppar γ Antagonist T0070907, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/T0070907/pm42998806-67-10-17
Average 95 stars, based on 1 article reviews
ppar γ antagonist t0070907 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
MedChemExpress t0070907 ppar gamma antagonist
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
T0070907 Ppar Gamma Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/T0070907/pm42993626-469-29-32
Average 95 stars, based on 1 article reviews
t0070907 ppar gamma antagonist - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

98
MedChemExpress gw9662 ppar gamma antagonist
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Gw9662 Ppar Gamma Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/GW9662/pm42993626-469-24-27
Average 98 stars, based on 1 article reviews
gw9662 ppar gamma antagonist - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

96
Proteintech anti γ ppar
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Anti γ Ppar, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR+gamma+Polyclonal+antibody/pm42903678-211-35-39
Average 96 stars, based on 1 article reviews
anti γ ppar - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech pparγ
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Pparγ, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR+gamma+Polyclonal+antibody/pm42883753-144-5-10
Average 96 stars, based on 1 article reviews
pparγ - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Proteintech mouse anti pparγ antibody
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Mouse Anti Pparγ Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR+gamma+Antibody/pm42882480-88-27-31
Average 94 stars, based on 1 article reviews
mouse anti pparγ antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology pparγ
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Pparγ, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR%CE%B3+Antibody/pm42883237-215-59-62
Average 96 stars, based on 1 article reviews
pparγ - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech rabbit polyclonal anti ppargamma
( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for <t>PPAR</t> isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.
Rabbit Polyclonal Anti Ppargamma, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ppar%CE%B3/PPAR+gamma+Polyclonal+antibody/pm42849439-227-124-127
Average 96 stars, based on 1 article reviews
rabbit polyclonal anti ppargamma - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for PPAR isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.

Journal: Science Advances

Article Title: Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

doi: 10.1126/sciadv.aee9754

Figure Lengend Snippet: ( A ) Chemical structure of VSP-51-2. ( B to D ) Subtype selectivity of VSP-51-2 for PPAR isozymes (α, δ, and γ) assessed by competitive TR-FRET binding assays. Specific agonists were used as positive controls: (B) GW7647 (PPARα), (C) GW0742 (PPARδ), and (D) Rosiglitazone (Rosi, PPARγ). ( E ) Quantitative binding affinity of VSP-51-2 for the PPARγ-ligand-binding domain (LBD). Rosi ( K i = 37.9 ± 2.1 nM) served as a full agonist control. ( F ) Transcriptional activation in COS-7 cells transiently transfected with a PPARγ -responsive luciferase reporter gene. Dose-dependent responses were measured after 24-hour treatment (30 pM to 10 μM). ( G ) Crystal structure of PPARγ LBD–VSP-51-2–PGC1α coactivator peptide ternary complex (2.6-Å resolution). Coloring: PPARγ LBD, green; VSP-51-2, pink. ( H ) Two-dimensional (2D) ligand interaction map of VSP-51-2 within the PPARγ LBD. Key contacts include hydrogen bonds between the amide-carboxyl pharmacophore and Tyr 327 /Lys 367 (dashed lines) and hydrophobic contacts with Ser 289 /Leu 340 . ( I ) Structural superposition of VSP-51-2 bound PPARγ with Rosi-bound PPARγ (cyan; PDB ID: 2PRG). Arrows highlight conformational differences in the β sheet region. ( J ) Comparison with SR1664-bound PPARγ (green; PDB ID: 4CN6) reveals distinct orientations of the TZD headgroup and positioning of helix H3. Data in (B) to (F) are presented as means ± SEM ( n = 3 biological replicates). Statistical analysis by nonlinear regression (GraphPad Prism v10.0) with 95% confidence intervals. *** P < 0.001.

Article Snippet: The primary antibodies used were against p-PPARγ (1:2000; Bioss, catalog no. bs-4888R), AKR1C3 (1:2000; Proteintech, catalog no. 11194-1-AP), and β-actin (1:2000; Cell Signaling Technology, CST, catalog no. 4967).

Techniques: Binding Assay, Ligand Binding Assay, Control, Activation Assay, Transfection, Luciferase, Comparison, Analysis

( A ) Schematic of the proposed mechanism by which PPARγ Ser 273 phosphorylation contributes to adipose tissue dysfunction in PCOS, created with FigDraw ( www.figdraw.com ). ( B ) VSP-51-2 suppresses PPARγ Ser 273 phosphorylation (p-PPARγ) in adipose tissue from DHEA-induced PCOS rats. Top, representative Western blot. Bottom, quantification of the p-PPARγ/PPARγ ratio. ( C ) mRNA levels of key adipogenic and lipogenic genes in rat adipose tissue. ( D ) Lipid accumulation in 3T3-L1 adipocytes treated with VSP-51-2 (10 μM, 48 hours). Top: Oil Red O staining. Bottom: Quantification of lipid droplets. Data are presented as means from three independent experiments. ( E ) Heatmap showing mRNA levels of lipogenic genes in 3 T3-L1 cells quantified by real-time PCR ( n = 3). ( F ) PPARγ dependency of VSP-51-2 effects on insulin-related gene expression in 3 T3-L1 adipocytes ( n = 3). Data are expressed as means ± SEM. Statistical significance determined by one-way ANOVA with Tukey’s post hoc test.

Journal: Science Advances

Article Title: Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

doi: 10.1126/sciadv.aee9754

Figure Lengend Snippet: ( A ) Schematic of the proposed mechanism by which PPARγ Ser 273 phosphorylation contributes to adipose tissue dysfunction in PCOS, created with FigDraw ( www.figdraw.com ). ( B ) VSP-51-2 suppresses PPARγ Ser 273 phosphorylation (p-PPARγ) in adipose tissue from DHEA-induced PCOS rats. Top, representative Western blot. Bottom, quantification of the p-PPARγ/PPARγ ratio. ( C ) mRNA levels of key adipogenic and lipogenic genes in rat adipose tissue. ( D ) Lipid accumulation in 3T3-L1 adipocytes treated with VSP-51-2 (10 μM, 48 hours). Top: Oil Red O staining. Bottom: Quantification of lipid droplets. Data are presented as means from three independent experiments. ( E ) Heatmap showing mRNA levels of lipogenic genes in 3 T3-L1 cells quantified by real-time PCR ( n = 3). ( F ) PPARγ dependency of VSP-51-2 effects on insulin-related gene expression in 3 T3-L1 adipocytes ( n = 3). Data are expressed as means ± SEM. Statistical significance determined by one-way ANOVA with Tukey’s post hoc test.

Article Snippet: The primary antibodies used were against p-PPARγ (1:2000; Bioss, catalog no. bs-4888R), AKR1C3 (1:2000; Proteintech, catalog no. 11194-1-AP), and β-actin (1:2000; Cell Signaling Technology, CST, catalog no. 4967).

Techniques: Phospho-proteomics, Tissue, Western Blot, Oil Red O Staining, Real-time Polymerase Chain Reaction, Gene Expression